Introduction
Lignocaine has become important in the management of many cardiac arrhythmias, particularly ventricular extrasystoles following myocardial infarction (Gianelly et at., 1967; Jewitt et al., 1968) , but despite its known cardiac depressant action (negative inotropic effect) (Binnion, 1968) it appears to be safe in acute myocardial infarction (Stannard et al., 1968) . When given in a dose of about 1 mg./kg. intravenously as a single injection or as an infusion at a rate of 1-2 mg./minute there are no appreciable haemodynamic effects in patients (Binnion, 1968; Stannard et at., 1968; Schumacher et al., 1968 ) though doses of 200-400 mg. intravenously given to anaesthetized dogs (about [8] [9] [10] [11] [12] [13] [14] [15] [16] mg./kg.) produce a pronounced fall in myocardial contractile force and may even produce electromechanical dissociation of cardiac activity such that a normal E.C.G. is present with no myocardial contraction (Binnion, 1968) .
In this paper are reported the plasma lignocaine levels determined in patients in whom the dose of drug used would cause no haemrodynamic effect, and in addition the levels reached in anaesthetized dogs where the myocardial depressant effect was pronounced. the sternal angle. Cardiac output was measured by injecting 2-5 mg. of indocyanine green into the pulmonary artery with withdrawal of arterial blood through a Gilford 103-1R densitometer by a Gilford 105-S pump. The dye curve, pressures, and an electrocardiogram were recorded on an ultraviolet or a photographic recorder (Binnion, 1968 The human and canine blood samples were centrifuged; the plasma was removed and stored at 40 C. until analysed. Plasma lignocaine levels were measured by gas chromatography in the laboratories of Astra A.B., Sweden.
Methods

Patients
Results
Patients
The rise in plasma lignocaine after 1 mg./kg. intravenously was not significant (Table I Table II . There is a slight rise in heart rate but no significant change in cardiac output, and, more particularly, there is no measurable fall in left ventricular maximum dp/dt at the end of the injection. Previous work has shown that the continuous infusion technique with the dosage used in these investigations causes no significant haemodynamic changes (Binnion, 1968) , and this was confirmed again with the larger group of patients. Maximum left ventricu'lar dp/dt.+2-0 (± 11-5) * P<0-05.
Dogs
No lignocaine was used to infiltrate the skin and all control plasma lignocaine levels were below 0-3 jkg./ml. (Table III) .
During the infusion at 13-S mg. of lignocaine per minute there was an increase in plsalevel to 7-03 jig./mll. after 30 minutes, and the 'level fell progressively over the next 20 minutes but was still raised at the end of the 20-minute period. Although the haemodynamic effects reported previously (Binnion, 1968) were essentially the same, maximum left ventricular dp/dt fell in the two dogs by an average of 8-7%, 11-1%, and 21-8% respectively after 10, 20, and 30 minutes of lignocaine infusion. Fig. 1 . In Fig. -2 (Binnion, 1968) Lecr II E.CG.. Larger intravenous infusions (13 5 mg. of fignocaine per mimite) given to anaesthetized dogs produced a plasma level of 7 fpg./ml. after 30 minutes, though the depressant effect of such a procedure on haemodynamics was only moderate and all animals recovered satisfactorily. This probably represents the safe maximum level which might be produced in patients and agrees with the work of Scott et al. (1968) . A rapid injection of 200 mg. of lignocaine produced a maximum plasma level of 13 8 jpg./ml., and this was associated with a pronounced decrease in myocardial contractile force, and if the amount given was doubled a maximum plasma level of 27.8 jPg./ml. was achieved with such severe diminution of myocardial contraction that death usually ensued. Death was due to fallure of the heart as a pump, though electrical activity proceeded fairly normally. Dissociation of the electrical and mechanical activity of the heart has also been reported to occur when the calcium/potassium interrelations have been upset experimentally (Lee et al., 1966) . This implies that lignocaine in toxic amounts interferes with the process of contraction of the cardiac muscle, and preliminary work suggests that this may be due to interference with calcium uptake by the sarcoplasmic reticulum (Baird and Binnion, unreported observatiohs) . Certainly substances such as adrenaline and isoprenaline incras calcium uptake by the sarcoplasmic reticulum and have a positive inotropic action, whereas lignocaine and other myocardial depressants like sodium pentobarbitone (Lain et al., 1968) reduce calcium uptake. It is the release of this calcium from the sarcoplasmic reticulum which causes the actin-myosin interaction and consequent muscle contraction.
Introduction
The clinical association between Addison's disease of the idiopathic type and various thyroid disorders is well established (Falta, 1912; Schmidt, 1926; Carpenter et al., 1964 of tuberculosis or of any other specific cause. Ten also showed clinical evidence of thyroid disease-two had myxoedema, five thyrotoxicosis, one a nodular goitre, one Hashimoto's disease, and one thyroiditis. Fifteen of the remaining 30 patients who did not have clinical evidence of thyroid disease agreed to attend for further investigation of their thyroid function. These investigations included fluorescent autoantibody tests carried out by applying serum to sections of various snapfrozen tissues and then staining for deposited. globulin. An estimation of the serum protein-bound iodine level was also included, and so was a four-jhour 132I thyroid uptake test carried out both before and 18 to 24 hours after stimulation with a single intramuscular injection of 2X5 units of thyrotrophin (Thytropar). This last was regarded as a test of thyroid reserve (Hobbs et,al., 1963) . Five patients who had Addison's disease of tuberculous origin were assessed in the same way, the results being compared with those found in 17 control subjects between the age of 15 and 59 years who had had thyrotrophin stimulation tests but did not show any evidence of either thyroid or adrenal disease.
Results
The details of the patients and results of the tests are shown in the 
